Brian Lehmann Archive — Page 1 of 1

Complex scatterplot titled “Transcriptional Breast Cancer Atlas,” showing colored clusters of points labeled Neuroendocrine, Mucinous, HER2E ER, HER2E KIS, LumB, LumA, Fibroblast ER, Immune-dominant, Basal M, Basal IM, Basal BL1, Stem-like, LAR, and Normal, with a compass rose in the lower-left corner.
November 3, 2026

Breast cancer atlas helps chart course for precision oncology

The new map integrates data from more than 7,600 tumors across 22 independent studies and reveals previously hidden forms of breast cancer that differ in prognosis, biology and treatment sensitivity.

By Leigh MacMillan
Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)
December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

The new combination significantly improved progression-free and overall survival of patients with metastatic triple-negative breast cancer.

By Tom Wilemon
November 18, 2021

‘Multi-omics’ reveals treatment option for breast cancer subtype

By Bill Snyder
February 27, 2020

Breast cancer study may help predict treatment response

Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.

By Bill Snyder
September 28, 2017

VICC investigators land support from Komen Foundation

Three breast cancer investigators from Vanderbilt-Ingram Cancer Center (VICC) have been awarded research grants from Susan G. Komen, a nonprofit foundation devoted to supporting cancer research, community health outreach, advocacy and public policy initiatives.

By Vanderbilt Health News
Syringe inserted into the bullseye of a black-and-yellow dartboard.
September 9, 2016

In search of new cancer targets

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.

By Leigh MacMillan